Mw: A Potential Non-Specific Vaccine as First Response to Future Viral Pandemics before SpecificVaccines are Available - Some Lessons from COVID-19 Pandemic
Abstract
In absence of an effective drug or vaccine in the initial phase of COVID-19 pandemic, authors started searching the literature to repurpose existing drugs/vaccines. Mw vaccine, a heat-killed Mycobacterium W, is routinely used by clinicians to boost the immune response of leprosy patients in India as an innate immune response immunomodulator. After detailed deliberations, on September 2020, the corresponding author submitted an emergency protocol to use Mw as a booster of Innate Immunity of doctors and HCWs looking after COVID-19 Positive patients in Himachal Pradesh, India. Later Mw was arranged and 21 persons were immunised with two site intradermal 0.1 mL doses of Mw vaccine in September 2020. Later two booster doses were given one each (0.1 mL) at 3 months’ interval. Regular RT-PCR was done and two persons who received vaccine were found to be positive for COVID-19. One person with diabetic status was found to have symptoms of sore throat, fatigue and high fever that responded in home isolation, without oxygen requirement and the other person was positive but asymptomatic. Subsequent studies proved that the prophylactic effect of Mw manifests quickly following the first administration of Mw, widening of the gap between two arms over time, reflecting ongoing immune remodelling. With the current COVID-19 vaccination schedule across the world and the emergence of breakthrough infection, Mw should be useful in the current pandemic too and must be tried. In future viral pandemic, we should think of using Mw as the first response non-specific vaccine till a specific vaccine is available, as Mw does not require antigen-specific changes and can be used immediately as universal vaccine. Mw stimulates innate response against viral mutation and variants as well.
How to cite this article:
Bharti O, Avhad A, Kishore J. Mw: A Potential Non-Specific Vaccine as First Response to Future Viral Pandemics before SpecificVaccines areAvailable - Some Lessons from COVID-19 Pandemic. Special Issue - COVID-19 & Other Communicable Disease. 2022;263-266.
DOI: https://doi.org/10.24321/0019.5138.202240
References
World Health Organization [Internet]. Coronavirus (COVID-19) Dashboard; [cited 2022 Jan 15]. Available from:https://covid19.who.int/
Cadila Pharmaceuticals Limited [Internet]. Sepsivac by Cadila; [cited 2022 Jan 15]. Available from: https://www.cadilapharma.com/sepsivac-sepsis-saviour-cadila/
Bharti OK.Emergency protocol to use Mw as booster of innate immunity of doctors and HCWs looking after COVID 19+ Patients in Himachal Pradesh, India.Research Proposal, 2020.
Kishore J, Grimes DS, Anderson DC, Bharti OK, Joseph B, Ghai G, Sahoo M. Recommendations for high vitamin D supplementation to help fight the COVID-19 pandemic and its inclusion in National COVID-19 management guidelines. Epidem Int. 2021;6(2):6-9. [Google Scholar]
Netea MG, DomÃnguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, Riksen NP, Schlitzer A, Schultze JL, Stabell Benn C, Sun JC, Xavier RJ, Latz E. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020 Jun;20(6):375-88. [PubMed] [Google Scholar]
Rehwinkel J, Tan CP, Goubau D, Schulz O, Pichlmair A, Bier K, Robb N, Vreede F, Barclay W, Fodor E, Reis e Sousa C. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell. 2010 Feb;140(3):397-408. [PubMed] [Google Scholar]
Goubau D, Deddouche S, Reis e Sousa C. Cytosolic sensing of viruses.Immunity. 2013 May;38(5):855-69. [PubMed] [Google Scholar]
Mantovani A, Netea MG. Trained innate immunity, epigenetics, and Covid-19. N Engl J Med. 2020;383(11):1078-80. [PubMed] [Google Scholar]
De Lang A, Osterhaus AD, Haagmans BL. Interferon-gamma and interleukin-4 downregulate expression of the ARS coronavirus receptor ACE2 in Vero E6 cells. Virology. 2006 Sep;353(2):474-81. [PubMed] [Google Scholar]
Jaiswal SR, Mehta A, Bhagwati G, Lakhchaura R, Aiyer H, Khamar B, Chakrabarti S. Innate immune response modulation and resistance to SARS-CoV-2 infection: aprospective comparative cohort study in high risk healthcare workers. medRxiv [Preprint]. 2020; [cited 2022 Jan 15]. Available from: https://www.medrxiv.org/content/10.1101/2020.10.20.20214965v1 [Google Scholar]
Kanani RC, Geetha SJ, Patel S, Khamar B, Honkala AT, Malhotra SV. Innate immune modulation and resistance to COVID-19.EJBPS. 2021;8(6):178-81.
Strongin AY, Sloutsky A, Cieplak P. A note on the potential BCG vaccination – COVID-19 molecular link. Coronaviruses. 2020;1:4. [Google Scholar]
Arts RJW, Moorlag SJCFM, Novakovic B, Li Y, Wang SY, Oosting M, Kumar V, Xavier RJ, Wijmenga C, Joosten LAB, Reusken CBEM, Benn CS, Aaby P, Koopmans MP, Stunnenberg HG, van Crevel R, Netea MG. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe. 2018 Jan;23(1):89-100.e5. [PubMed] [Google Scholar]
Shet A, Ray D, Malavige N, Santosham M, Bar-Zeev N. Differential COVID-19-attributable mortality and BCG vaccine use in countries.medRxiv [Preprint]. 2020; ; [cited 2022 Jan 15]. Available from: https://www.medrxiv.org/content/10.1101/2020.04.01.20049478v1 [Google Scholar]
Mohapatra PR, Mishra B, Behera B. BCG vaccination induced protection from COVID-19. Indian J Tuberc. 2021 Jan;68(1):119-24. [PubMed] [Google Scholar]
Curtis N, Sparrow A, TedrosAGhebreyesus TA, Netea MG. Considering BCG vaccination to reduce the impact of COVID-19.Lancet. 2020 May;395(10236):1545-6. [PubMed] [Google Scholar]
Ahmed SM, Nasr MA, Elshenawy SE, Hussein AE, El-Betar AH, Mohamed RH, El-Badri N. BCG vaccination and the risk of COVID 19: a possible correlation. Virology. 2022 Jan;565:73-81. [PubMed] [Google Scholar]
Sehgal IS, Bhalla A, Puri GD, Yaddanapudi LN, Singh M, Malhotra P, Dhooria S, Suri V, Agarwal R. Safety of an immunomodulatorMycobacterium w in COVID-19. Lung India. 2020 May-Jun;37(3):279-81. [PubMed] [Google Scholar]
Copyright (c) 2022 Author's
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
